ASCO GU 2019 Press Releases

Viewing 1-9 of 9 articles

Seattle Cancer Care Alliance Physicians to Present their Research at Genitourinary Cancers Symposium

ASCO GU 2019: Phase 3 Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: The ARCHES Trial

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men with Metastatic Prostate Cancer

African-American Men with Advanced Prostate Cancer Live Longer Compared With White Men When Treated with Newer Hormone Therapies

Pembrolizumab Plus Axitinib Extended Overall Survival and Progress-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer